- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03981575
Vaststelling van biomarkers en klinische eindpunten bij myotone dystrofie type 1 (END-DM1)
Building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN), the present study seeks to overcome insufficient data on natural history; lack of reliable biomarkers; and incomplete characterization and limited biological understanding of the phenotypic heterogeneity of Myotonic Dystrophy 1 by examining strategies to improve the reliability by making further refinements in our sample collection and analysis procedures by developing strategies for managing patient heterogeneity going forward.
Funding Source- FDA OOPD
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Approximately 700 adult participants (18 to 70 years old, inclusive) with DM1 will be enrolled at 15 centers (up to 70 patients will be recruited at each site). No treatment will be administered as part of this study. Participants will receive standard of care as determined by the investigators. Study visits occur at baseline/0 months, 12 months, and 24 months. Few restrictions are placed on participation in the study because the investigators aim to capture the full spectrum of disease severity.
Muscle biopsy sub-study: Studies of splicing biomarkers in muscle biopsy samples will be conducted on a subset of 95 participants. These participants will have an additional study visit at 3 months.
Longitudinal muscle biopsy sub-study: Up to 30 individuals who have had a prior muscle biopsy as part of a DMCRN study will be asked to undergo another biopsy greater than 24 months after the prior biopsy. These participants will have an additional ad hoc biopsy visit.
COVID-19 sub-study: To evaluate severity of illness and response to COVID-19 vaccination in DM1 patients compared to corresponding data available about the general population, END-DM1 study participants will be asked to complete a one-time survey about COVID-19 experiences. A subset of those participants' blood samples will be analyzed to understand immunoglobulin response to infection and vaccination in DM1 patients.
Actigraphy sub-study: To assess daily physical activity in individuals with DM1 and evaluate physical activity changes over a 12-24 month period related to disease progression, a subset of participants will be asked to wear a small, wireless activity monitor while performing functional assessments described in the main study. Those participants will be asked to wear the activity monitor for 7 days following their research visit. Those participants will be asked to complete additional questionnaires.
Handheld Dynamometry sub-study: To evaluate additional muscle strength methods, a subset of participants will be asked to complete additional strength testing using either the MEDup or MicroFET handheld dynamometry device on the same day as their END-DM1 main study visit. Those participants will be asked to return to the clinic for a second visit within 10 days of the END-DM1 study visit to repeat the handheld dynamometry assessments and complete additional strength measures.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Ruby Langeslay
- Telefoonnummer: 804-828-8481
- E-mail: ruby.langeslay@vcuhealth.org
Studie Contact Back-up
- Naam: Jennifer Raymond
- Telefoonnummer: 804-828-6318
- E-mail: jennifer.raymond@vcuhealth.org
Studie Locaties
-
-
-
Québec, Canada
- Actief, niet wervend
- Université de Sherbrooke
-
-
-
-
-
München, Duitsland
- Werving
- Friedrich Baur Institute, Ludwig-Maximilians-Universität München
-
Contact:
- Benedikt Schoser
- Telefoonnummer: +49 (0)89 4400 57400
- E-mail: benedikt.schoser@med.lmu.ede
-
Hoofdonderzoeker:
- Benedikt Schoser, FEAN
-
Contact:
- Corinna Wirner-Piotrowski
- Telefoonnummer: +49 89 4400 57400
- E-mail: Corinna.Wirner@med.uni-muenchen.de
-
-
-
-
-
Milan, Italië
- Voltooid
- Centro Clinico NeMO
-
-
-
-
-
Nijmegen, Nederland
- Werving
- Radboud University Medical Center
-
Contact:
- Baziel vanEngelen
- Telefoonnummer: (024) 366 8374
- E-mail: Baziel.vanEngelen@radboudumc.nl
-
Hoofdonderzoeker:
- Baziel van Engelen, MD
-
Contact:
- Monique Plieger
- E-mail: Monique.Plieger@radboudumc.nl
-
-
-
-
-
Auckland, Nieuw-Zeeland
- Werving
- University of Auckland
-
Hoofdonderzoeker:
- Richard Roxburgh
-
Contact:
- Miriam Rodrigues
- Telefoonnummer: 021896662
- E-mail: mrodrigues@adhb.govt.nz
-
Contact:
- Neerja Singh
- E-mail: neerja.singh@auckland.ac.nz
-
-
-
-
-
London, Verenigd Koninkrijk
- Werving
- University College London
-
Contact:
- Chris Turner
- E-mail: chris.turner7@nhs.net
-
Hoofdonderzoeker:
- Chris Turner
-
Contact:
- Iqraa Afzal
- E-mail: iqraa.afzal@nhs.net
-
London, Verenigd Koninkrijk
- Werving
- St. George's, University of London
-
Contact:
- Emma Matthews
- Telefoonnummer: 020 8725 4162
- E-mail: ematthew@sgul.ac.uk
-
Hoofdonderzoeker:
- Emma Matthews
-
-
-
-
California
-
La Jolla, California, Verenigde Staten, 92703
- Werving
- University of California, San Diego
-
Hoofdonderzoeker:
- Chamindra Laverty, MD
-
Contact:
- Elizabeth Moreno
- E-mail: e4moreno@health.ucsd.edu
-
Contact:
- Gabriella Penner
- E-mail: gpenner@health.ucsd.edu
-
Los Angeles, California, Verenigde Staten, 90095
- Werving
- University of California, Los Angeles
-
Hoofdonderzoeker:
- Perry Shieh, MD, PhD
-
Contact:
- Dennis Fernando
- Telefoonnummer: 310-825-3264
- E-mail: DeFernando@mednet.ucla.edu
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80204
- Werving
- University of Colorado - Denver
-
Contact:
- Alyssa Avilez
- Telefoonnummer: 303-724-4644
- E-mail: alyssa.avilez@cuanschutz.edu
-
Contact:
- Brianna Blume
- Telefoonnummer: 303-724-6386
- E-mail: brianna.blume@cuanschutz.edu
-
Hoofdonderzoeker:
- Matthew Wicklund, MD
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32611
- Werving
- University of Florida
-
Hoofdonderzoeker:
- Sankarsubramoney Subramony, MD
-
Contact:
- Donovan Lott
- E-mail: djlottpt@phhp.ufl.edu
-
Contact:
- Whitney Miller
- E-mail: whitney.miller@neurology.ufl.edu
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- Werving
- University of Iowa
-
Hoofdonderzoeker:
- Andrea Swenson, MD
-
Contact:
- Maegan Tyrrell
- Telefoonnummer: 319-356-8323
- E-mail: maegan-tyrrell@uiowa.edu
-
Contact:
- Loraine Brenner
- E-mail: loraine-brenner@uiowa.edu
-
-
Kansas
-
Kansas City, Kansas, Verenigde Staten, 66160
- Werving
- Kansas University Medical Center
-
Hoofdonderzoeker:
- Jeffrey Statland, MD
-
Contact:
- Michaela Walker
- E-mail: mwalker20@kumc.edu
-
Contact:
- Rebecca Clay
- E-mail: rclay@kumc.edu
-
-
New York
-
Rochester, New York, Verenigde Staten, 14642
- Werving
- University of Rochester
-
Contact:
- Jeanne Dekdebrun
- Telefoonnummer: 585-276-4611
- E-mail: Jeanne_dekdebrun@urmc.rochester.edu
-
Hoofdonderzoeker:
- Johanna Hamel, MD
-
Contact:
- Jim Hilbert
- Telefoonnummer: 585-273-5590
- E-mail: james_hilbert@urmc.rochester.edu
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43210
- Werving
- Ohio State University
-
Contact:
- Kaneshia Hives
- Telefoonnummer: 614-685-5661
- E-mail: Kaneshia.Hives@osumc.edu
-
Contact:
- Lischele Watkins
- E-mail: lischele.watkins@osumc.edu
-
Hoofdonderzoeker:
- Bakri Elsheikh, MD
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Houston Methodist Neurological Institute
-
Hoofdonderzoeker:
- Erika P. Greene
-
Contact:
- Kadeesia Brown
- Telefoonnummer: 346-238-2295
- E-mail: kbrown5@houstonmethodist.org
-
-
Virginia
-
Richmond, Virginia, Verenigde Staten, 23298
- Werving
- Virginia Commonwealth University
-
Hoofdonderzoeker:
- Nicholas Johnson, MD
-
Contact:
- Jodie Howell
- E-mail: jodie.howell@vcuhealth.org
-
Contact:
- Carino Jennings
- E-mail: Carino.Garza@vcuhealth.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
DM1 has a prevalence rate of approximately 1 per 2,300. There are no expected gender differences. Both men and women will be selected for this study.
Children with DM1 are not included in this project because the pathophysiological basis of congenital and childhood DM1 appears to be mechanistically distinct.
Beschrijving
Inclusion criteria:
- Age 18 to 70 (inclusive)
- Competent to provide informed consent
- Clinical diagnosis of DM1 based on research criteria1 or positive genetic test
- Comment: The clinical research criteria require myotonia, muscle weakness in a characteristic distribution, and history of similar findings in a first degree relative. Genetic testing confirmed the diagnosis of DM1 in > 99% of individuals who satisfied these criteria.2
Exclusion criteria:
- Symptomatic renal or liver disease, uncontrolled diabetes or thyroid disorder, or active malignancy other than skin cancer.
- Current alcohol or substance abuse
- Concurrent enrollment in clinical trial for DM1, or participation in trial within 6 months of entry.
- Concurrent pregnancy or planned pregnancy during the course of the study.
- Concurrent medical condition that would, in the opinion of the investigator or clinical evaluator, compromise performance on study measures.
- Note: non-ambulatory participants are not excluded, but are limited to <15% of enrollment.
Inclusion criteria for participants in the muscle biopsy sub-study:
• Of the 95 patients undergoing the tibialis anterior muscle biopsy, at least half will have at least moderate weakness of ankle dorsiflexion, defined as MRC score ≤ 4+. This is in order to obtain a muscle tissue sample in a person more severely affected with myotonic dystrophy. Approximately 10 patients at each site will undergo the muscle biopsy.
Exclusion criteria for 95 participants in the muscle biopsy sub-study:
- Known CTG repeat expansion size less than 100 repeats, unless there are clear cut signs of limb weakness and muscle wasting. This is in order to obtain a muscle tissue sample in a person more severely affected with myotonic dystrophy.
- Use of anticoagulant such as warfarin or a direct oral anticoagulant (e.g. dabigatran) due to the increased risk of bleeding.
- Use of aspirin or non-steroidal anti-inflammatory agents should be discontinued 3 days prior to the biopsy procedure, if possible.
- Platelet count <50,000 (if known) due to the increased risk of bleeding.
- History of a bleeding disorder due to the increased risk of bleeding.
- Advanced wasting of tibialis anterior (TA) muscle that precludes needle muscle biopsy in order to ensure that a sample taken would be of muscle and not just fat and fascia.
- Previous muscle biopsy of either TA in order to provide muscle tissue samples of non-biopsied muscles.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: OTHER
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
|---|
|
Study Visits
Patients will receive standard of care as determined by their treating physician. Study visits occur at baseline/0 months, 12 months, and 24 months |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in ambulation over 24 months as measured by the 10 meter walk (m/s).
Tijdsspanne: 12 and 24 months
|
10 meter walk will be measured (m/s) |
12 and 24 months
|
|
Change in respiratory function over 24 months as measured by spirometry, specifically the supine forced vital capacity (FVC).
Tijdsspanne: 12 and 24 months
|
Supine forced vital capacity (% predicted) |
12 and 24 months
|
|
Percent splicing of DM1-affected splice events
Tijdsspanne: 3 months
|
RNA sequenced of muscle biopsy samples collected at two different times will be combined and used to calculate a percent splicing index (PMI) |
3 months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Longitudinal Muscle Biopsy Sub-study: Characterization of RNA splicing measures over a prolonged period of time (>24 months)
Tijdsspanne: 24 months
|
RNA sequenced of muscle biopsy samples collected at two different times will be combined and used to calculate a percent splicing index (PMI) |
24 months
|
|
Longitudinal Muscle Biopsy Sub-study: Characterization of functional endpoints over a prolonged period of time (>24 months)
Tijdsspanne: 24 months
|
10-meter walk/run, grip strength, ADF (ankle dorsiflexion) strength, supine FVC (forced vital capacity) |
24 months
|
|
COVID-19 Sub-study: Data from DM1 patients or caregivers about COVID-19 illness and vaccination experience, severity of illness and response to vaccination in DM1 patients compared to corresponding data available about the general population.
Tijdsspanne: 24 months
|
To evaluate the severity and rate of COVID-19 infection in patients with DM1 compared to the general population symptomatic response to COVID-19 vaccination in DM1 patients |
24 months
|
|
COVID-19 Sub-study: Immunoglobulin profile and measles titers, and COVID-19 IgG titers
Tijdsspanne: 24 months
|
To understand immunoglobulin response to infection and vaccination in DM1 patients |
24 months
|
|
Actigraphy Sub-study: Feasibility of measuring daily physical activity in individuals with DM1 in a multi-site study
Tijdsspanne: 24 months
|
Participants will be asked to wear an activity monitor for 7 days following their in-clinic END-DM1 study visit to evaluate whether this type of activity monitoring is feasible in future trials. |
24 months
|
|
Actigraphy Sub-study: Objective daily physical activity using wireless accelerometry (ActiGraph), and comparison to normative values and patient reported physical activity.
Tijdsspanne: 24 months
|
Participants will be asked to wear an activity monitor for 7 days following their in-clinic END-DM1 study visit and report physical activity, to establish physical activity data in the DM1 population. |
24 months
|
|
Actigraphy Sub-study: Physical activity changes over a 12-24 month period related to disease progression.
Tijdsspanne: 24 months
|
Participants will wear the wireless activity monitor during the functional and strength measures, and complete additional study questionnaires at their regular END-DM1 study visits. |
24 months
|
|
Handheld Dynamometry Sub-study: Inter-rater reliability, standard error of measurement, and minimal detectable change of Maximal Isometric Muscle Strength force values obtained with the MEDup and MicroFET handheld dynamometers in adults with DM1
Tijdsspanne: 24 months
|
Participants will be assessed using either the MEDup or MicroFET handheld dynamometer on the same day as an END-DM1 main study visit. Participants will complete a second visit +/- 10 days from that visit where HHD will be assessed using the same HHD method (either MEDup or MicroFET) used at the HHD visit. Additional functional and strength assessments will be captured at this visit. |
24 months
|
|
Handheld Dynamometry Sub-study: Comparison of quantitative muscle strength testing feasibility and validity between MEDup and MicroFET with the existing Fixed-QMT currently used in the END-DM1 study protocol.
Tijdsspanne: 24 months
|
Data captured for MEDup and MicroFET will be compared to data collected using the Fixed-QMT measures in the main END-DM1 study. |
24 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Nicholas Johnson, MD, Virginia Commonwealth University
- Hoofdonderzoeker: Charles Thornton, MD, University of Rochester
Publicaties en nuttige links
Algemene publicaties
- Leeuwenberg KE, Sansone VA, Hamel J, Hung M, Dekdebrun JM, Lizio A, Eichinger K, Gagnon C, Roxburgh RH, Subramony SH, Statland JM, Elsheikh BH, Turner C, Matthews EL, Ragole TE, Sampson JB, Schoser B, Takahashi MP, Wicklund MP, Swenson AJ, Laverty CG, Shieh PB, Greene EP, Raymond J, DeSpain E, Thornton CA, Mul K, Johnson NE; Myotonic Dystrophy Clinical Research Network. Prospective Study of Video Hand Opening Time as a Quantitative Measurement of Myotonia in Patients With Myotonic Dystrophy Type 1. Neurology. 2026 Apr 14;106(7):e214747. doi: 10.1212/WNL.0000000000214747. Epub 2026 Feb 26.
- Mul K, Eichinger K, Hung M, Sansone VA, Gagnon C, Subramony S, Roxburgh RH, Hamel J, Statland JM, Elsheikh B, Turner C, Sampson J, Ragole T, Matthews E, Schoser B, Swenson A, Laverty C, Shieh P, Greene EP, Takahashi M, Wicklund M, Dekdebrun J, Raymond J, DeSpain E, Thornton CA, Johnson NE; Myotonic Dystrophy Clinical Research Network. Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study. PLoS One. 2025 Dec 11;20(12):e0331163. doi: 10.1371/journal.pone.0331163. eCollection 2025.
- Provenzano M, Ikegami K, Bates K, Gaynor A, Hartman JM, Jones A, Butler A, Berggren KN, Dekdebrun J, Hung M, Lapato DM, Kiefer M, Thornton CA, Johnson NE, Hale MA; Myotonic Dystrophy Clinical Research Network (DMCRN). The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1. J Clin Invest. 2025 Jan 7;135(4):e185426. doi: 10.1172/JCI185426.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Musculoskeletale aandoeningen
- Ziekten van het zenuwstelsel
- Spierziekten
- Neuromusculaire aandoeningen
- Genetische ziekten, aangeboren
- Neurodegeneratieve ziekten
- Heredodegeneratieve aandoeningen, zenuwstelsel
- Spieraandoeningen, atrofisch
- Spierdystrofieën
- Myotone aandoeningen
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Myotone dystrofie
Andere studie-ID-nummers
- HM20014419
- DMCRN (Andere identificatie: University of Rochester)
- FD-R-006071 (Ander subsidie-/financieringsnummer: OPD)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Aggregated and deidentified data will be shared with qualified investigators upon majority approval of the DMCRN investigators.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .